Synergistic bacterial compositions and methods of production and use thereof
Inventors
Henn, Matthew R. • von Maltzahn, Geoffrey • D'Onofrio, Anthony Mario • Litcofsky, Kevin Daniel • Berry, David Arthur • Cook, David N. • Afeyan, Noubar B. • Aunins, John Grant
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
Core Innovation
The disclosed invention uses defined, purified gut-bacterial compositions to restore microbiota function and inhibit pathogens, with particular emphasis on synergistic combinations for treating or preventing recurrent Clostridium difficile infection. The claimed method uses a therapeutic composition comprising a first purified bacterial population related by 16S rDNA sequence identity to a reference Collinsella aerofaciens OTU and a second purified bacterial population related to a reference bacterium of the family Clostridiaceae listed in Table 1.
The problem addressed is dysbiosis and the need to restore microbiota function while inhibiting pathogens, particularly Clostridium difficile associated with recurrent infection. The patent describes a synergistic combination of the bacterial populations that is cytotoxic or cytostatic to Clostridium difficile. Reported screening results include inhibition of Clostridium difficile by tested binary pairs and ternary combinations.
Claims Coverage
The provided relevant claims identify one independent claim, covering a method of treating an occurrence or recurrence of Clostridium difficile infection using two purified bacterial populations whose synergistic combination is cytotoxic or cytostatic to the bacterium.
Synergistic purified bacterial populations for treating Clostridium difficile infection
The claim covers administering a therapeutic composition comprising a first purified bacterial population with a 16S rDNA sequence at least about 97% identical to a sequence in a reference Collinsella aerofaciens OTU, and a second purified bacterial population with a 16S rDNA sequence at least about 97% identical to a sequence in a reference bacterium of the family Clostridiaceae listed in Table 1. The synergistic combination is cytotoxic or cytostatic to Clostridium difficile.
The independent claim centers on treating an occurrence or recurrence of Clostridium difficile infection with two sequence-defined purified bacterial populations whose synergistic combination is cytotoxic or cytostatic to the pathogen.
Stated Advantages
The synergistic combination is cytotoxic or cytostatic to Clostridium difficile. A dependent claim also describes a detectable reduction in the number of Clostridium difficile bacteria in or excreted from the gastrointestinal tract within one month after administration.
Documented Applications
Treating an occurrence or recurrence of Clostridium difficile infection in a human subject.
Interested in licensing this patent?